Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Long-term remissions in refractory ITP patients by daratumumab

View Full Paper
Ask AI
Bookmark
Share

Authors

RWRalph Wäsch

Discussion

Loading...

Member takes

Overview

Observational study found daratumumab effectively improves responses in refractory ITP, suggesting a new therapy option.

Key Points

  • To evaluate the effectiveness of daratumumab in patients with refractory immune thrombocytopenic purpura (ITP).
  • Treated eight patients with refractory ITP using daratumumab (1800 mg doses) since 2020.
  • Administered a median of 9.5 treatment applications per patient, with various further regimens.
  • Assessed platelet counts and defined treatment response as a count of ≥50 Gpt/L.
  • Five out of eight patients (62.5%) responded to daratumumab therapy, with complete remissions observed.
  • Median time to response was two weeks; some had sustained remission up to 51 months.
  • Two patients relapsed, but one achieved a second remission with daratumumab and romiplostim combination therapy.

Cite This Study

Ralph Wäsch (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e55dhttps://doi.org/10.1182/blood-2025-3032
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A case for CD38 targeted therapy in multi-refractory immune thrombocytopenia2025
  2. 2Daratumumab for relapsed refractory immune thrombotic thrombocytopenic purpura: initial response and long-term follow-up.2026
  3. 3Safety and Efficacy of Daratumumab in Immune Thrombocytopenia2025 · 16 citations
  4. 4Targeting CD38 in immune thrombocytopenia: Rationale and a scoping review of daratumumab2026
  5. 5Efficacy and safety of daratumumab in multiresistant immune‐mediated thrombotic thrombocytopenic purpura2024 · 13 citations